RISEDRONATE TEVA 35 MG

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Compra

Foglio illustrativo Foglio illustrativo (PIL)
18-03-2018

Principio attivo:

RISEDRONIC ACID AS SODIUM

Commercializzato da:

ABIC MARKETING LTD, ISRAEL

Codice ATC:

M05BA07

Forma farmaceutica:

TABLETS

Composizione:

RISEDRONIC ACID AS SODIUM 35 MG

Via di somministrazione:

PER OS

Tipo di ricetta:

Required

Prodotto da:

TEVA PHARMACEUTICAL WORKS PRIVATE LIMITED COMPANY, HUNGARY

Gruppo terapeutico:

RISEDRONIC ACID

Area terapeutica:

RISEDRONIC ACID

Indicazioni terapeutiche:

Treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. Treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. Prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. Treatment of osteoporosis in men at high risk of fracture.

Data dell'autorizzazione:

2011-10-31

Foglio illustrativo

                                RISE TAB PL SH 060218
RISE TAB PL SH 060218
THIS LEAFLET FORMAT HAS BEEN
DETERMINED BY THE MINISTRY OF
HEALTH AND THE CONTENT THEREOF
HAS BEEN CHECKED AND APPROVED
PATIENT PACKAGE INSERT
IN ACCORDANCE WITH THE
PHARMACISTS' REGULATIONS
(PREPARATIONS) - 1986
The dispensing of this medicine
requires a doctor's prescription.
READ THE PACKAGE INSERT CAREFULLY
IN ITS ENTIRETY BEFORE USING THIS
MEDICINE.
RISEDRONATE TEVA
® 35 MG
TABLETS
COMPOSITION
Each tablet contains:
Risedronate Sodium 35 mg
_Inactive ingredients:_
Lactose monohydrate, pregelatinized
starch, maize starch, colloidal silicon
dioxide, sodium stearyl fumarate,
magnesium stearate, polyvinyl
alcohol, titanium dioxide (E171),
macrogol, talc, iron oxide yellow
(E172), iron oxide red (E172).
Each tablet contains 139.9 mg
lactose.
THERAPEUTIC GROUP
Risedronate belongs to a group of
medicines called bisphosphonates.
THERAPEUTIC ACTIVITY
Risedronate
is
used
to
treat
and
prevent
osteoporosis
in
postmenopausal women and for
treatment of osteoporosis in men at
high risk of fractures.
WHEN SHOULD THE PREPARATION
NOT BE USED?
Do not use Risedronate if you are
pregnant, planning to become
pregnant or breastfeeding.
Do not use Risedronate if you are
sensitive to any of its ingredients.
Do not take this medicine if you
are unable to remain in an upright
position (standing or sitting) for at
least 30 minutes after taking the
medicine.
Do not use this medicine if you
have difficulty swallowing for any
reason.
Do not use this medicine if you are
suffering from hypocalcemia (a low
blood calcium level).
Do not use this medicine in patients
suffering from severe renal failure
(creatinine clearance less than
30 ml/min).
This medicine contains lactose,
therefore should not be used
if you suffer from problems of
galactose intolerance, lactase
deficiency, or glucose and lactose
malabsorption.
DO NOT TAKE THIS MEDICINE WITHOUT
CONSULTING A DOCTOR BEFORE
STARTING TREATMENT
If you are suffering or have suffered in
the past from impaired function of the
kidney, the esophagus, from d
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Foglio illustrativo Foglio illustrativo arabo 18-03-2018
Foglio illustrativo Foglio illustrativo ebraico 18-03-2018

Cerca alert relativi a questo prodotto